• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

    3/25/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $LUCD alert in real time by email

    Lucid processed record test volume, saw rapid initial uptake in concierge medicine contracts, and secured first commercial insurance coverage policies 

    Veris Health secured financing to resume advancement of implantable physiological monitor through FDA clearance and commercial launch 

    PAVmed completed debt restructuring and Lucid deconsolidation to regain Nasdaq compliance and strengthen balance sheet

    Conference call and webcast to be held today, March 25th, at 8:30 AM EDT

    NEW YORK, March 25, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and reported financial results for the fourth quarter and full year ended December 31, 2024.

    PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. (PRNewsfoto/PAVmed Inc.)

    Conference Call and Webcast

    The webcast will take place on Tuesday, March 25, 2025, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com.  Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "PAVmed Business Update" to join.

    Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com.

    Business Update Highlights

    "Following the critical steps taken to stabilize PAVmed's corporate structure and balance sheet, PAVmed is now in a very strong position to operate as it was designed—as a diversified commercial life sciences company with multiple independently-financed subsidiaries operating under a shared services model," said Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer. "With Lucid and Veris both having sufficient capital to advance their commercial strategies, we expect PAVmed to directly benefit from their success. The performance of PAVmed's subsidiaries, particularly Lucid and its recent achievements with EsoGuard, serve as key drivers of PAVmed's long-term success and sustainability."

    Highlights from the fourth quarter and recent weeks:

    • Lucid Diagnostics, PAVmed's single largest asset, continues to deliver operational milestones and drive increased market value (link to Lucid press release), thereby strengthening PAVmed's balance sheet:
      • Recognized $1.2 million in EsoGuard® Esophageal DNA Test revenue for 4Q24 and processed a single-quarter record of 4,042 EsoGuard tests, which represents a 45% sequential increase and 84% annual increase.
      • Executed over 20 cash-pay concierge medicine contracts in the first few weeks following the launch of new sales channels targeting contractually-guaranteed revenue.
      • Secured first positive commercial insurance coverage policy for EsoGuard from Highmark Blue Cross Blue Shield, and an agreement with Blue Cross Blue Shield of Rhode Island to pay for EsoGuard under state biomarker legislation.
      • Updated National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines now includes a section on esophageal precancer screening.
      • CLUE and ENVET-BE clinical utility studies accepted for peer-reviewed publication, further strengthening EsoGuard's already robust clinical evidence package.
      • Case Western Reserve University and University Hospitals investigators awarded $8 million NIH grant to study EsoGuard for expanded indication in patients without GERD, potentially increasing the total addressable market opportunity beyond the current ~$60 billion.
      • Completed a convertible debt refinancing and common stock financing, yielding sufficient net proceeds to extend cash runway beyond key reimbursement milestones.
      • Regained compliance with Nasdaq minimum bid price requirement for continued listing on the Nasdaq Capital Market.
    • PAVmed and Veris completed private placement financing with gross proceeds of approximately $2.4 million at a Veris pre-money valuation of $35 million. Proceeds will be used to resume efforts to advance implantable physiological monitor through FDA clearance and commercial launch, and supplements a recent $1.8 million NIH grant.
    • Veris' pilot program with The Ohio State's James Cancer Hospital extended through April 2025. Definitive long-term strategic and commercial agreement imminent.
    • PMX Incubator is engaged in ongoing discussions with both financial and strategic investors regarding a direct investment to finance PortIO.
    • PAVmed regained compliance with Nasdaq minimum equity requirement through the deconsolidation of Lucid and the restructuring of PAVmed's convertible debt, which will add approximately $25 million to PAVmed's equity in 1Q25.

    Financial Results:

    • For the three months ended December 31, 2024, PAVmed's revenues reflect approximately 125 patients on the Veris Cancer Care Platform. EsoGuard-related revenues are no longer consolidated with PAVmed's results due to the deconsolidation effective September 10, 2024. PAVmed's management service income from Lucid Diagnostics, amounting to $3.2 million post-deconsolidation, is reflected in Other Income. Operating expenses were approximately $5.2 million, which includes stock-based compensation expenses of $0.7 million. GAAP net income attributable to common stockholders was approximately $1.3 million, or approximately $0.12 per common share on a diluted basis
    • As shown below, and for the purpose of illustrating the effect of stock-based compensation and other non-cash income and expenses on the Company's financial results, the Company's non-GAAP adjusted loss was approximately $0.7 million, or $(0.06) per common share.
    • As of December 31, 2024, PAVmed had cash and cash equivalents of $1.2 million. On a pro forma basis, including the first quarter 2025 private placement, PAVmed's cash is approximately $3.6 million to begin 2025.
    • The audited financial results for the year ended December 31, 2024 were filed with the SEC on Form 10-K on March 24, 2025, and are available at www.pavmed.com or www.sec.gov.

    PAVmed Non-GAAP Measures

    • To supplement our financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company's financial results. These non-GAAP financial measures include net loss before interest, taxes, depreciation, and amortization (EBITDA) and non-GAAP adjusted loss, which further adjusts EBITDA for stock-based compensation expense, loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, and loss on debt extinguishment. The foregoing non-GAAP financial measures of EBITDA and non-GAAP adjusted loss are not recognized terms under U.S. GAAP.
    • Non-GAAP financial measures are presented with the intent of providing greater transparency to the information used by us in our financial performance analysis and operational decision-making. We believe these non-GAAP financial measures provide meaningful information to assist investors, shareholders, and other readers of our financial statements in making comparisons to our historical financial results and analyzing the underlying performance of our results of operations. These non-GAAP financial measures are not intended to be, and should not be, a substitute for, considered superior to, considered separately from, or as an alternative to, the most directly comparable GAAP financial measures.
    • Non-GAAP financial measures are provided to enhance readers' overall understanding of our current financial results and to provide further information for comparative purposes. Management believes the non-GAAP financial measures provide useful information to management and investors by isolating certain expenses, gains, and losses that may not be indicative of our core operating results and business outlook. Specifically, the non-GAAP financial measures include non-GAAP adjusted loss, and its presentation is intended to help the reader understand the effect of the loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, the loss on debt extinguishment and the corresponding accounting for non-cash charges on financial performance. In addition, management believes non-GAAP financial measures enhance the comparability of results against prior periods.
    • A reconciliation to the most directly comparable GAAP measure of all non-GAAP financial measures included in this press release for the three months and year ended December 31, 2024 and 2023 are as follows:

     

    Condensed Consolidated Statement of Operations (Unaudited)





    For the three months ended

    December 31,



    For the year ended

    December 31,





    2024



    2023



    2024



    2023

    (in thousands except per-share amounts)

















    Revenue



    $                  10



    $             1,049



    $             2,995



    $             2,452

    Operating expenses



    5,198



    17,433



    47,482



    71,247

    Other (Income) Expense



    (6,330)



    1,024



    (72,914)



    10,468

    Net (Income) Loss



    (1,142)



    17,408



    (28,427)



    79,263

    Net income (loss) per common share, diluted



    $               0.12



    $             (1.98)



    $               0.50



    $             (9.16)

    Net income (loss) attributable to common stockholders



    1,346



    (15,905)



    31,966



    (66,270)

    Preferred Stock dividends and deemed dividends



    85



    1,869



    7,825



    2,095

    Net income (loss) as reported



    1,431



    (14,036)



    39,791



    (64,175)

    Adjustments:

















    Depreciation and amortization expense1



    69



    725



    1,198



    2,932

    Interest expense, net2



    4



    (80)



    (209)



    84

    NCI ownership share of Interest and Depreciation adjustments



    —



    (133)



    (229)



    (608)

    EBITDA



    1,504



    (13,524)



    40,551



    (61,767)



















    Other non-cash or financing related expenses:

















    Stock-based compensation expense3



    733



    1,968



    6,449



    11,139

    ResearchDx acquisition/settlement paid in stock1



    —



    —



    —



    713

    Operating expenses issued in stock1



    150



    —



    598



    625

    Gain on deconsolidation of subsidiary



    —



    —



    (72,287)



    —

    Change in FV equity method investments



    (125)



    —



    (532)



    —

    Change in FV convertible debt2



    (2,950)



    255



    (462)



    6,026

    Offering costs convertible debt2



    —



    —



    —



    1,186

    Loss on debt extinguishment2



    —



    750



    2,535



    3,782

    Debt modification expense



    —



    —



    2,000



    —

    NCI ownership share of non-GAAP adjustments



    —



    (103)



    (1,262)



    (2,860)

    Non-GAAP adjusted (loss)



    $              (688)



    $         (10,654)



    $         (22,410)



    $         (41,156)

    Non-GAAP shares outstanding, basic and diluted



    10,819



    8,014



    9,672



    7,232

    Non-GAAP adjusted (loss) income per share, basic and diluted



    $(0.06)



    $(1.33)



    $(2.32)



    $(5.69)



    1 Included in general and administrative expenses in the financial statements.

    2 Included in other income and expenses.

    3 Stock-based compensation ("SBC") expense included in operating expenses is detailed as follows in the table below by category within operating expenses for the non-GAAP Net operating expenses:

     

    Reconciliation of GAAP Operating Expenses to Non-GAAP Net Operating Expenses

    (in thousands except per-share amounts)



    For the three months ended

    December 31,



    For the year ended

    December 31,





    2024



    2023



    2024



    2023



















    Cost of revenue



    $                  48



    $             1,610



    $             4,840



    $             6,420

    Stock-based compensation expense3



    —



    (35)



    (112)



    (122)

    Net cost of revenue



    48



    1,575



    4,728



    6,298



















    Amortization of acquired intangible assets



    —



    505



    559



    2,021



















    Sales and marketing



    155



    4,690



    11,627



    17,583

    Stock-based compensation expense3



    (18)



    (413)



    (1,100)



    (1,715)

    Net sales and marketing



    137



    4,277



    10,527



    15,868



















    General and administrative



    4,188



    7,032



    24,524



    30,947

    Depreciation expense



    (69)



    (220)



    (639)



    (911)

    ResearchDx acquisition/settlement paid in stock



    —



    —



    —



    (713)

    Operating expenses issued in stock



    (150)



    —



    (598)



    (625)

    Stock-based compensation expense3



    (653)



    (1,175)



    (4,370)



    (7,935)

    Net general and administrative



    3,316



    5,637



    18,917



    20,763



















    Research and development



    807



    3,596



    5,932



    14,276

    Stock-based compensation expense3



    (62)



    (345)



    (867)



    (1,367)

    Net research and development



    745



    3,251



    5,065



    12,909



















    Total operating expenses



    5,198



    17,433



    47,482



    71,247

    Depreciation and amortization expense



    (69)



    (725)



    (1,198)



    (2,932)

    ResearchDx acquisition/settlement paid in stock



    —



    —



    —



    (713)

    Operating expenses issued in stock



    (150)



    —



    (598)



    (625)

    Stock-based compensation expense3



    (733)



    (1,968)



    (6,449)



    (11,139)

    Net operating expenses



    $             4,246



    $           14,740



    $           39,237



    $           55,838



















    About PAVmed and its Subsidiaries

    PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics Inc. (NASDAQ:LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.

    For more and for more information about PAVmed, please visit pavmed.com.

    For more information about Lucid Diagnostics, please visit luciddx.com.

    For more information about Veris Health, please visit verishealth.com. 

    Forward-Looking Statements

    This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed's and Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed's and Lucid's common stock; PAVmed's Series Z warrants; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed's and Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's and Lucid's clinical and preclinical studies; whether and when PAVmed's and Lucid's products are cleared by regulatory authorities; market acceptance of PAVmed's and Lucid's products once cleared and commercialized; PAVmed's and Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's and Lucid's future operations, see Part I, Item 1A, "Risk Factors," in PAVmed's and Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by PAVmed or Lucid after its most recent Annual Report. PAVmed and Lucid disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/pavmed-provides-business-update-and-reports-fourth-quarter-and-full-year-2024-financial-results-302410070.html

    SOURCE PAVmed Inc.

    Get the next $LUCD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LUCD
    $PAVM

    CompanyDatePrice TargetRatingAnalyst
    Lucid Diagnostics Inc.
    $LUCD
    12/27/2021$16.00Buy
    Ascendiant Capital
    Lucid Diagnostics Inc.
    $LUCD
    12/15/2021$17.00 → $13.00Buy
    Needham
    Lucid Diagnostics Inc.
    $LUCD
    11/8/2021$18.00Buy
    Canaccord Genuity
    Lucid Diagnostics Inc.
    $LUCD
    11/8/2021$14.00Buy
    BTIG Research
    Lucid Diagnostics Inc.
    $LUCD
    11/8/2021$21.00Overweight
    Cantor Fitzgerald
    Lucid Diagnostics Inc.
    $LUCD
    11/8/2021$17.00Buy
    Needham
    More analyst ratings

    $LUCD
    $PAVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Matheis Dennis bought $457,607 worth of shares (350,000 units at $1.31), increasing direct ownership by 40% to 565,443 units (SEC Form 4)

      4/A - Lucid Diagnostics Inc. (0001799011) (Issuer)

      5/23/25 4:14:42 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • Director Matheis Dennis bought $457,607 worth of shares (350,000 units at $1.31) (SEC Form 4)

      4 - Lucid Diagnostics Inc. (0001799011) (Issuer)

      5/22/25 4:45:49 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • New insider Tasso Partners, Llc claimed ownership of 2,574,350 shares (SEC Form 3)

      3 - PAVmed Inc. (0001624326) (Issuer)

      3/14/25 7:53:09 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care

    $LUCD
    $PAVM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Matheis Dennis bought $457,607 worth of shares (350,000 units at $1.31), increasing direct ownership by 40% to 565,443 units (SEC Form 4)

      4/A - Lucid Diagnostics Inc. (0001799011) (Issuer)

      5/23/25 4:14:42 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • Director Matheis Dennis bought $457,607 worth of shares (350,000 units at $1.31) (SEC Form 4)

      4 - Lucid Diagnostics Inc. (0001799011) (Issuer)

      5/22/25 4:45:49 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care

    $LUCD
    $PAVM
    SEC Filings

    See more
    • PAVmed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - PAVmed Inc. (0001624326) (Filer)

      6/24/25 8:15:29 AM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Lucid Diagnostics Inc. (0001799011) (Filer)

      6/18/25 5:00:40 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • PAVmed Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - PAVmed Inc. (0001624326) (Filer)

      6/18/25 5:00:38 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care

    $LUCD
    $PAVM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ascendiant Capital initiated coverage on Lucid Diagnostics with a new price target

      Ascendiant Capital initiated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $16.00

      12/27/21 6:21:16 AM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • Needham reiterated coverage on Lucid Diagnostics with a new price target

      Needham reiterated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $13.00 from $17.00 previously

      12/15/21 6:36:10 AM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • Canaccord Genuity initiated coverage on Lucid Diagnostics with a new price target

      Canaccord Genuity initiated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $18.00

      11/8/21 10:16:23 AM ET
      $LUCD
      Medical/Dental Instruments
      Health Care

    $LUCD
    $PAVM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing

      Private placement yields $2.5 million from the sale of Veris Health common stock at a $35 million pre-money valuation. NEW YORK, June 24, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiary, Veris Health Inc. ("Veris"), today announced the completion of a private placement equity financing directly into Veris, yielding $2.5 million in proceeds (gross and net). This supplements a prior $2.4 million financing completed earlier this year.

      6/24/25 8:01:00 AM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test

      Lucid to partner with Hoag in its mission to eradicate esophageal cancer by expanding access to EsoGuard precancer testing across its extensive healthcare delivery network NEW YORK, June 18, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that Hoag, a nationally-recognized regional healthcare delivery network, has launched a comprehensive, integrated esophageal precancer testing program using Lucid Diagnostics' EsoGuard® Esophageal DNA Test. Lucid will partner with Hoag to offer EsoGuard testing across its digestive health, prim

      6/18/25 12:02:00 PM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

      Long-term strategic partnership and commercial transition follow successful completion of pilot program of Veris Cancer Care Platform™ at OSUCCC – James NEW YORK, June 3, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced that Veris has entered into a strategic partnership agreement with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), a National Ca

      6/3/25 8:31:00 AM ET
      $PAVM
      Medical/Dental Instruments
      Health Care

    $LUCD
    $PAVM
    Leadership Updates

    Live Leadership Updates

    See more
    • Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

      NEW YORK, May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. "We are pleased that Lucid is joining these importa

      5/27/25 7:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements

      Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D. to board to replace departing directors NEW YORK, Sept. 16, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that, as part of its efforts to regain compliance with Nasdaq's listing requirements, Lucid Diagnostics (NASDAQ:LUCD) ("Lucid") will be deconsolidated from PAVmed's financial statements.  As a result, PAVmed will no longer report consolidated financials reflecting Lucid's operating losses. PAVmed's holdings of Lucid common stock remain

      9/16/24 4:30:00 PM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

      Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the U.S., which encompasses hospitals, a physician group, and an affiliated health plan NEW YORK, May 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the Company has closed a Series B-1 Preferred Stock offering led by one of the Company's long-time institutional investors, with gross proceeds of $11.6 million, bringing

      5/7/24 7:39:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care

    $LUCD
    $PAVM
    Financials

    Live finance-specific insights

    See more
    • PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results

      Lucid secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash Veris Health completed 1Q25 financing, resumed development of implantable physiological monitor, and will soon launch first commercial partnership with major cancer center PAVmed seeking to leverage infrastructure and expand into biopharma sector; actively evaluating clinical and late preclinical stage assets Conference call and webcast to be held today, May 15th, at 8:30 AM EDT NEW YORK, May 15, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical

      5/15/25 8:01:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, May 1, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ), PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Compa

      5/1/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Wednesday, May 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's first quarter 2025 finan

      4/30/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care

    $LUCD
    $PAVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Lucid Diagnostics Inc.

      SC 13D/A - Lucid Diagnostics Inc. (0001799011) (Subject)

      12/12/24 4:30:32 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by PAVmed Inc.

      SC 13G - PAVmed Inc. (0001624326) (Subject)

      11/14/24 10:02:46 AM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by PAVmed Inc.

      SC 13G - PAVmed Inc. (0001624326) (Subject)

      9/23/24 8:46:15 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care